Drug details

Lorbrena (lorlatinib tablets)

type of Antineoplastics, Anaplastic Lymphoma Kinase Inhibitors

Lorbrena (lorlatinib) is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or alectinib as the first ALK inhibitor therapy for metastatic disease; or ceritinib as the first ALK inhibitor therapy for metastatic disease.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• fever,
• shortness of breath,
• chills,
• rapid breathing,
• wheezing,
• thoughts of self-harm,
• sudden dizziness,
• unusual changes in mood or behavior,
• cough with mucus,
• dry cough,
• hallucinations, and
• numbness, tingling, or burning pain in your hands or feet,
• sudden chest pain,
• problems with speech, thought, or memory

The following drugs are related to Lorbrena, either as a replacement or used together:

• Gilotrif (afatinib tablets, for oral use)
• Alecensa (alectinib capsules)
• Alimta (pemetrexed)
• Zykadia (ceritinib hard-gelatin capsules)
• Cyramza (ramucirumab solution for intravenous infusion)
• Tafinlar (dabrafenib capsules)
• Vizimpro (dacomitinib)
• Exkivity (mobocertinib capsules)
• Keytruda (pembrolizumab for injection)
• Lumakras (sotorasib tablets)
• Zepzelca (lurbinectedin for injection)
• Mustargen (mechlorethamine hcl)
• Mekinist (trametinib tablets)
• Tepmetko (tepotinib tablets)